Amphastar Pharmaceuticals (AMPH) Accounts Payables (2013 - 2026)

Amphastar Pharmaceuticals' Accounts Payables history runs 14 years deep, the most recent figure standing at $152.7 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 13.22% year-over-year to $152.7 million; the TTM figure through Mar 2026 stood at $152.7 million (down 13.22% YoY), while the FY2025 annual figure was $148.3 million, down 5.55% from the prior year.
• Accounts Payables was $152.7 million for Q1 2026 at Amphastar Pharmaceuticals, up from $148.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $217.5 million in Q2 2023 to a low of $20.0 million in Q3 2022.
• Historically, Accounts Payables has averaged $111.9 million across 5 years, with a median of $131.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables sank 77.55% in 2022, then surged 517.41% in 2024.
• A 5-year view of Accounts Payables shows it stood at $84.2 million in 2022, then slumped by 69.8% to $25.4 million in 2023, then soared by 517.41% to $157.1 million in 2024, then fell by 5.55% to $148.3 million in 2025, then climbed by 2.93% to $152.7 million in 2026.
• The last three Accounts Payables figures came in at $152.7 million (Q1 2026), $148.3 million (Q4 2025), and $190.8 million (Q3 2025), per Business Quant data.